The control operated by the cell cycle machinery on mef2 stability contributes to the downregulation of cdkn1a and entry into s phase

Molecular and Cellular Biology

Volumn 35, Issue 9, 2015, Pages 1633-1647

  Di Giorgio, Eros ^a   Gagliostro, Enrico ^a   Clocchiatti, Andrea ^a   Brancolini, Claudio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE H3; MYOCYTE ENHANCER FACTOR 2; P21 ACTIVATED KINASE; PROTEASOME; SERINE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; MEF2C PROTEIN, HUMAN; S PHASE KINASE ASSOCIATED PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; DNA REPLICATION; EPIGENETICS; FIBROBLAST; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; UBIQUITINATION; ANIMAL; CELL LINE; CHEMISTRY; CYTOLOGY; DOWN REGULATION; GENETICS; METABOLISM;

MURINAE;

ANIMALS; CELL CYCLE; CELL LINE; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; FIBROBLASTS; HUMANS; MEF2 TRANSCRIPTION FACTORS; MICE; PROTEIN STABILITY; S PHASE; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 84929152028     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01461-14     Document Type: Article

References (49)

1. Potthoff MJ, Olson EN. 2007. MEF2: a central regulator of diverse developmental programs. Development 134:4131-4140. http://dx.doi.org/10.1242/dev.008367.
2. Yu YT. 1996. Distinct domains of myocyte enhancer binding factor-2A determining nuclear localization and cell type-specific transcriptional activity. J Biol Chem 271:24675-24683.
3. Wales S, Hashemi S, Blais AMJ. 2014. Global MEF2 target gene analysis in cardiac and skeletal muscle reveals novel regulation of DUSP6 by p38MAPK-MEF2 signaling. Nucleic Acids Res 42:11349-11362. http://dx.doi.org/10.1093/nar/gku813.
4. Sandmann T, Jensen LJ, Jakobsen JS, Karzynski MM, Eichenlaub MP, Bork P, Furlong EEM. 2006. A temporal map of transcription factor activity: Mef2 directly regulates target genes at all stages of muscle development. Dev Cell 10:797-807. http://dx.doi.org/10.1016/j.devcel.2006.04.009.
5. Shalizi A, Gaudillière B, Yuan Z, Stegmüller J, Shirogane T, Ge Q, Tan Y, Schulman B, Harper JW, Bonni A. 2006. A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 311: 1012-1017. http://dx.doi.org/10.1126/science.1122513.
6. Clocchiatti A, Di Giorgio E, Ingrao S, Meyer-Almes F-J, Tripodo C, Brancolini C. 2013. Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER_ breast tumors. FASEB J 27:942-954. http://dx.doi.org/10.1096/fj.12-209346.
7. Di Giorgio E, Clocchiatti A, Piccinin S, Sgorbissa A, Viviani G, Peruzzo P, Romeo S, Rossi S, Dei Tos AP, Maestro R, Brancolini C. 2013. MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation. Mol Cell Biol 33:4473-4491. http://dx.doi.org/10.1128/MCB.01050-13.
8. Barneda-Zahonero B, Román-González L, Collazo O, Rafati H, Islam ABMMK, Bussmann LH, Di Tullio A, De Andres L, Graf T, López-Bigas N, Mahmoudi T, Parra M. 2013. HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages. PLoS Genet 9:e1003503. http://dx.doi.org/10.1371/journal.pgen.1003503
9. Lyons GE, Micales BK, Schwarz J, Martin JF, Olson EN. 1995. Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. J Neurosci 15:5727-5738.
10. Li H, Radford JC, Ragusa MJ, Shea KL, McKercher SR, Zaremba JD, Soussou W, Nie Z, Kang Y-J, Nakanishi N, Okamoto S, Roberts AJ, Schwarz JJ, Lipton SA. 2008. Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo. Proc Natl Acad Sci U S A 105:9397-9402. http://dx.doi.org/10.1073/pnas.0802876105.
11. Liu N, Nelson BR, Bezprozvannaya S, Shelton JM, Richardson JA, Bassel-Duby R, Olson EN. 2014. Requirement of MEF2A, C, and D for skeletal muscle regeneration. Proc Natl Acad Sci U S A 111:4109-4114. http://dx.doi.org/10.1073/pnas.1401732111.
12. Wilker PR, Kohyama M, Sandau MM, Albring JC, Nakagawa O, Schwarz JJ, Murphy KM. 2008. Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. Nat Immunol 9:603-612. http://dx.doi.org/10.1038/ni.1609.
13. Suzuki E, Guo K, Kolman M, Yu YT, Walsh K. 1995. Serum induction of MEF2/RSRF expression in vascular myocytes is mediated at the level of translation. Mol Cell Biol 15:3415-3423.
14. Han TH, Prywes R. 1995. Regulatory role of MEF2D in serum induction of the c-jun promoter. Mol Cell Biol 15:2907-2915.
15. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. 1997. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 16:7054-7066. http://dx.doi.org/10.1093/emboj/16.23.7054.
16. Mendoza-Maldonado R, Paolinelli R, Galbiati L, Giadrossi S, Giacca M. 2010. Interaction of the retinoblastoma protein with orc1 and its recruitment to human origins of DNA replication. PLoS One 5:e13720. http://dx.doi.org/10.1371/journal.pone.0013720.
17. Paroni G, Mizzau M, Henderson C, Del Sal G, Schneider C, Brancolini C. 2004. Caspase-dependent regulation of histone deacetylase 4 nuclearcytoplasmic shuttling promotes apoptosis. Mol Biol Cell 15:2804-2818. http://dx.doi.org/10.1091/mbc. E03-08-0624.
18. Henderson CJ, Aleo E, Fontanini A, Maestro R, Paroni G, Brancolini C. 2005. Caspase activation and apoptosis in response to proteasome inhibitors. Cell Death Differ 12:1240-1254. http://dx.doi.org/10.1038/sj.cdd.4401729.
19. Frescas D, Pagano M. 2008. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8:438-449. http://dx.doi.org/10.1038/nrc2396.
20. Carrano AC, Eytan E, Hershko A, Pagano M. 1999. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1:193-199. http://dx.doi.org/10.1038/12013.
21. Marinissen MJ, Chiariello M, Pallante M, Gutkind JS. 1999. A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. Mol Cell Biol 19:4289-4301.
22. Liu W, Wu G, Li W, Lobur D, Wan Y. 2007. Cdh1-anaphase-promoting complex targets Skp2 for destruction in transforming growth factor betainduced growth inhibition. Mol Cell Biol 27:2967-2979. http://dx.doi.org/10.1128/MCB.01830-06.
23. Yu ZK, Gervais JL, Zhang H. 1998. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci U S A 95:11324-11329. http://dx.doi.org/10.1073/pnas.95.19.11324.
24. Arnold MA, Kim Y, Czubryt MP, Phan D, McAnally J, Qi X, Shelton JM, Richardson JA, Bassel-Duby R, Olson EN. 2007. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell 12:377-389. http://dx.doi.org/10.1016/j.devcel.2007.02.004.
25. 1 and S phases. Nat Rev Mol Cell Biol 14:518-528. http://dx.doi.org/10.1038/nrm3629.
26. Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK. 2013. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154:556-568. http://dx.doi.org/10.1016/j.cell.2013.06.048.
27. 1/S progression of the cellcycle. J Biol Chem 276:30423-30428. http://dx.doi.org/10.1074/jbc. M101194200.
28. Wu J, Lingrel JB. 2004. KLF2 inhibits Jurkat T leukemia cell growth via up-regulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1. Oncogene 23:8088-8096. http://dx.doi.org/10.1038/sj.onc.1207996.
29. Dunham I, Kundaje A, Aldred SF, et al. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489:57-74. http://dx.doi.org/10.1038/nature11247.
30. Zentner GE, Tesar PJ, Scacheri PC. 2011. Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res 21:1273-1283. http://dx.doi.org/10.1101/gr.122382.111.
31. Zheng M, Zhu J, Lu T, Liu L, Sun H, Liu Z, Tian J. 2013. P300-mediated histone acetylation is essential for the regulation of gata4 and MEF2C by BMP2 in H9c2 cells. Cardiovasc Toxicol 13:316-322. http://dx.doi.org/10.1007/s12012-013-9212-4.
32. McDermott JC, Cardoso MC, Yu YT, Andres V, Leifer D, Krainc D, Lipton SA, Nadal-Ginard B. 1993. hMEF2C gene encodes skeletal muscle-and brain-specific transcription factors. Mol Cell Biol 13:2564-2577.
33. Karamboulas C, Dakubo GD, Liu J, De Repentigny Y, Yutzey K, Wallace VA, Kothary R, Skerjanc IS. 2006. Disruption of MEF2 activity in cardiomyoblasts inhibits cardiomyogenesis. J Cell Sci 119:4315-4321. http://dx.doi.org/10.1242/jcs.03186.
34. Barbosa AC, Kim M-S, Ertunc M, Adachi M, Nelson ED, McAnally J, Richardson JA, Kavalali ET, Monteggia LM, Bassel-Duby R, Olson EN. 2008. MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function. Proc Natl Acad Sci U S A 105:9391-9396. http://dx.doi.org/10.1073/pnas.0802679105.
35. Canté-Barrett K, Pieters R, Meijerink JPP. 2014. Myocyte enhancer factor 2C in hematopoiesis and leukemia. Oncogene 33:403-410. http://dx.doi.org/10.1038/onc.2013.56.
36. Clark RI, Tan SWS, Péan CB, Roostalu U, Vivancos V, Bronda K, Pilátová M, Fu J, Walker DW, Berdeaux R, Geissmann F, Dionne MS. 2013. XMEF2 is an in vivo immune-metabolic switch. Cell 155:435-447. http://dx.doi.org/10.1016/j.cell.2013.09.007.
37. Chan SF, Sances S, Brill LM, Okamoto S-I, Zaidi R, McKercher SR, Akhtar MW, Nakanishi N, Lipton SA. 2014. ATM-dependent phosphorylation of MEF2Dpromotes neuronal survival afterDNAdamage. J Neurosci 34:4640-4653. http://dx.doi.org/10.1523/JNEUROSCI.2510-12.2014.
38. Cavanaugh JE, Ham J, Hetman M, Poser S, Yan C, Xia Z. 2001. Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci 21:434-443.
39. Magli A, Angelelli C, Ganassi M, Baruffaldi F, Matafora V, Battini R, Bachi A, Messina G, Rustighi A, Del Sal G, Ferrari S, Molinari S. 2010. Proline isomerase pin1 represses terminal differentiation and myocyte enhancer factor 2C function in skeletal muscle cells. J Biol Chem 285: 34518-34527. http://dx.doi.org/10.1074/jbc. M110.104133.
40. 1. Cell 98:859-869. http://dx.doi.org/10.1016/S0092-8674(00)81519-6.
41. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, Zhai H, Vidal M, Gygi SP, Braun P, Sicinski P. 2011. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 20:620-634. http://dx.doi.org/10.1016/j.ccr.2011.10.001.
42. Zhang M, Truscott J, Davie J. 2013. Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells. Mol Cancer 12:150. http://dx.doi.org/10.1186/1476-4598-12-150.
43. Li Y, Jenkins CW, Nichols MA, Xiong Y. 1994. Cell-cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261-2268.
44. Eckner R, Yao TP, Oldread E, Livingston DM. 1996. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev 10:2478-2490. http://dx.doi.org/10.1101/gad.10.19.2478.
45. Slepak TI, Webster KA, Zang J, Prentice H, O'Dowd A, Hicks MN, Bishopric NH. 2001. Control of cardiac-specific transcription by p300 through myocyte enhancer factor-2D. J Biol Chem 276:7575-7585. http://dx.doi.org/10.1074/jbc. M004625200.
46. Molinari S, Relaix F, Lemonnier M, Kirschbaum B, Schäfer B, Buckingham M. 2004. A novel complex regulates cardiac actin gene expression through interaction of Emb, a class VI POU domain protein, MEF2D, and the histone transacetylase p300. Mol Cell Biol 24:2944-2957. http://dx.doi.org/10.1128/MCB.24.7.2944-2957.2004.
47. 1 phase to allow cell-cycle progression. Curr Biol 16: 1171-1182. http://dx.doi.org/10.1016/j.cub.2006.04.044.
48. Zhao W, Zhao SP, Peng DQ. 2012. The effects of myocyte enhancer factor 2A gene on the proliferation, migration and phenotype of vascular smooth muscle cells. Cell Biochem Funct 30:108-113. http://dx.doi.org/10.1002/cbf.1823.
49. 1 cyclins ensures coherent cell-cycle entry. Nature 454:291-296. http://dx.doi.org/10.1038/nature07118.